Disclosures: Bridget Keenan: Genentech: Travel, Genentech: Grant/Research Support, Apexigen (now Pyxis Oncology): Grant/Research Support, Regeneron: Consultant, Regeneron: Grant/Research Support, Innovative Cellular Therapeutics: Grant/Research Support, Antengene: Grant/Research Support, AstraZeneca: Grant/Research Support, Partner Therapeutics: Grant/Research Support, Takeda: Grant/Research Support, Bryan Khuong Le: Nothing to Disclose, Quincy Harris: Nothing to Disclose, Jocelin Chen: Nothing to Disclose, Alexander Cheung: Nothing to Disclose, Zenghua Fan: Nothing to Disclose, Frances Lara: Nothing to Disclose, John Gordan: Nothing to Disclose, Paige Bracci: Nothing to Disclose, Spencer Behr: Nothing to Disclose, Lawrence Fong: Nothing to Disclose, Alan Venook: Nothing to Disclose, Edward Kim: Nothing to Disclose, Robin Kelley: Astra Zeneca: Grant/Research Support, Bayer: Grant/Research Support, Bristol Meyer Squibb: Grant/Research Support, Exelixis: Grant/Research Support, Eli Lilly: Grant/Research Support, Genentech/Roche: Grant/Research Support, Genentech/Roche: Grant/Research Support, GSK: Consultant, Kinnate: Consultant, J Pharma Inc.: Consultant, Loxo Oncology: Grant/Research Support, Merck: Grant/Research Support, Merck: Advisor, Moderna: Consultant, Partner Therapeutics: Grant/Research Support, Relay Therapeutics: Grant/Research Support, Surface Oncology: Grant/Research Support, Tyra Biosciences: Grant/Research Support, Regeneron: Consultant, Tyra Biosciences: Consultant, Compass Therapeutics: Grant/Research Support, Compass Therapeutics: Consultant, Servier: Grant/Research Support 986 EFFICACY OF NITAZOXANIDE (NTZ) IN PATHOGEN-ASSOCIATED MOLECULAR PATTERNS (PAMPS)-INDUCED DISEASE MODELS Marie Bobowski-Gerard 1 Debaecker Simon 1 Philippe Delataille 1 Philippe POULAIN 1 Yacine Hajji 1 Sakina Sayah Jeanne 1 Dean Hum 1 David Dombrowicz 2 Vanessa Legry 1 Bart Staels 2 , 1 Genfit S.A., Loos, France, 2 INSERM U1011, Univ
When Key Decisions Occur in Willows Intake-Led Program 4
The 28-day timeline applies to Wegovy (single-dose) when stored at room temperature before use, not Ozempic
It has been studied safely for up to 12 weeks at doses of 0.8 to 1 gram three times daily
The area under the tongue has a rich supply of blood vessels, which allows the medication to bypass the digestive system and liver
